Table 2.
Cost-effectiveness of antibiotics for treatment of cSSSI patients
| Treatment strategy | Total cost (USD) | Incremental cost (USD) | Total LY | LY saveda | ICER per LY saved |
|---|---|---|---|---|---|
| Vancomycin | 15,254 | 7.52 | |||
| SXT/rifampicin | 13,419 | -1836 | 7.68 | 0.16 | Dominant |
| Linezolid | 16,387 | 1133 | 7.92 | 0.40 | 2833 |
| Tedizolid | 17,353 | 2099 | 7.90 | 0.38 | 5523 |
| Daptomycin | 17,238 | 1984 | 7.84 | 0.32 | 6200 |
| Ceftaroline | 17,971 | 2717 | 7.82 | 0.30 | 9057 |
cSSSI complicated skin and soft structure infection, USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio, SXT trimethoprim/sulfamethoxazole
aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin